Calendario›BIIB›Diroximel Fumarate · EXPER-CA/IL

Diroximel Fumarate · EXPER-CA/IL

Exploring Diroximel Fumarate Real-world Experience in Canada and Israel

Ensayo de BIOGEN INC. en Relapsing Forms of MS (del registro, en inglés).

Fase

no aplica

Estado

Interrumpido

Participantes

64

previstos

Centros

6

Fin del objetivo primario

abr 2023

fecha real

Qué significa cada fase y cada estado.

Estudio observacional. Comenzó en dic 2021.

Este ensayo se detuvo. Motivo declarado por el promotor (del registro, en inglés): «Sponsor Decision».

Qué mide

Percentage of Participants on Treatment with DRF (del registro, en inglés) (año 1)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThe primary objective of the study is to characterize the persistence to therapy in participants with relapsing forms of multiple sclerosis (RMS) treated with diroximel fumarate (DRF) in routine clinical practice. The secondary objectives of the study are to assess short-term persistence to treatment; to assess long-term persistence on treatment; to assess the effect of DRF on relapses; to assess the impact of DRF on cognition; to assess the impact of DRF on participant reported outcomes (PROs); to assess the impact of DRF on disability; to assess treatment satisfaction with DRF; to explore the real-world safety profile of DRF (i.e., gastrointestinal \[GI\] tolerability, lymphocyte dynamics, adverse events \[AEs\] leading to discontinuation, and serious adverse events \[SAEs\].

Más ensayos de BIIB

Todos los de BIIB, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT04948606), actualizada en may 2023.